Fungal infections, named mycosis, can cause severe invasive and systemic diseases that
can even lead to death. In recent years, epidemiological data have recorded an increase in …

With increasing numbers of patients needing intensive care or who are immunosuppressed,
infections caused by moulds other than Aspergillus spp or Mucorales are increasing …

We reviewed the licensed antifungal drugs and summarized their mechanisms of action,
pharmacological profiles, and susceptibility to specific fungi. Approved antimycotics inhibit 1 …

An increasing number of critically ill patients are immunocompromised. Acute hypoxemic
respiratory failure (ARF), chiefly due to pulmonary infection, is the leading reason for ICU …

Background Isavuconazole is a novel triazole with broad-spectrum antifungal activity. The
SECURE trial assessed efficacy and safety of isavuconazole versus voriconazole in patients …

Abstract The European Society for Clinical Microbiology and Infectious Diseases, the
European Confederation of Medical Mycology and the European Respiratory Society Joint …

Background Fungal infections of the central nervous system (FIs-CNS) have become
significantly more common over the past 2 decades. Invasion of the CNS largely depends on …

Schizophyllum commune is a common basidiomycetous bracket fungus growing on rotten
wood, and is an occasional human pathogen, principally associated with sinusitis, allergic …

Abstract Species of Scedosporium and Lomentospora are considered as emerging
opportunists, affecting immunosuppressed and otherwise debilitated patients, although …

Prior to 1981, treatment options for invasive fungal infections were limited and associated
with significant toxicities. The introduction of ketoconazole marked the beginning of an era of …